Unlike HER2+ breast cancer or TNBC, neoadjuvant chemotherapy is not clearly recommended for patients with HR+HER2- breast cancer who have 1–2 suspicious ALN metastases on pre-treatment breast MRI. Here, ERBB2 is linked to breast carcinoma.